Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khanna, R.
Right arrow Articles by Potter, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khanna, R.
Right arrow Articles by Potter, P. M.
[Cancer Research 60, 4725-4728, September 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Proficient Metabolism of Irinotecan by a Human Intestinal Carboxylesterase1

Ruchi Khanna, Christopher L. Morton, Mary K. Danks and Philip M. Potter2

Department of Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105

Irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11)] is metabolized by esterases to yield the potent topoisomerase I poison 7-ethyl-10-hydroxycamptothecin. One of the major side effects observed with CPT-11 is gastrointestinal toxicity, and we supposed that this might be due to local activation of CPT-11 within the gut. Carboxylesterase (CE) activity was detected in human gut biopsies, and extracts of these tissues converted CPT-11 to 7-ethyl-10-hydroxycamptothecin in vitro. Expression of a human intestinal CE cDNA in COS-7 cells produced extracts that demonstrated proficient CPT-11 activation and conferred sensitivity of cells to CPT-11. These results suggest that gut toxicity from CPT-11 may be due in part to direct drug conversion by CEs present within the small intestine.




This article has been cited by other articles:


Home page
 JCOHome page
L. M. Wagner, J. G. Villablanca, C. F. Stewart, K. R. Crews, S. Groshen, C. P. Reynolds, J. R. Park, J. M. Maris, R. A. Hawkins, H. E. Daldrup-Link, et al.
Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study
J. Clin. Oncol., March 10, 2009; 27(8): 1290 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Dalvie, W. Chen, C. Zhang, A. D. Vaz, T. A. Smolarek, L. M. Cox, J. Lin, and R. S. Obach
Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans
Drug Metab. Dispos., November 1, 2008; 36(11): 2185 - 2198.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Schiel, S.-l. Green, W. I. Davis, P. C. Sanghani, W. F. Bosron, and S. P. Sanghani
Expression and Characterization of a Human Carboxylesterase 2 Splice Variant
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Danks, K. J. Yoon, R. A. Bush, J. S. Remack, M. Wierdl, L. Tsurkan, S. U. Kim, E. Garcia, M. Z. Metz, J. Najbauer, et al.
Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma
Cancer Res., January 1, 2007; 67(1): 22 - 25.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. N. Tallman, K. K. Miles, F. K. Kessler, J. N. Nielsen, X. Tian, J. K. Ritter, and P. C. Smith
The Contribution of Intestinal UDP-Glucuronosyltransferases in Modulating 7-Ethyl-10-hydroxy-camptothecin (SN-38)-Induced Gastrointestinal Toxicity in Rats
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 29 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Hyatt, L. Tsurkan, M. Wierdl, C. C. Edwards, M. K. Danks, and P. M. Potter
Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Mol. Cancer Ther., September 1, 2006; 5(9): 2281 - 2288.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. J. Schaaf, L. A. Hammond, S. J. Tipping, R. M. Goldberg, R. Goel, J. G. Kuhn, L. L. Miller, L. D. Compton, L. A. Cisar, G. L. Elfring, et al.
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Clin. Cancer Res., June 15, 2006; 12(12): 3782 - 3791.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. J. Yoon, J. Qi, J. S. Remack, K. G. Virga, M. J. Hatfield, P. M. Potter, R. E. Lee, and M. K. Danks
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Mol. Cancer Ther., June 1, 2006; 5(6): 1577 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. L. Furman, K. R. Crews, C. Billups, J. Wu, A. J. Gajjar, N. C. Daw, C. C. Patrick, C. Rodriguez-Galindo, C. F. Stewart, J. S. Dome, et al.
Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors
J. Clin. Oncol., February 1, 2006; 24(4): 563 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Imai, M. Imoto, H. Sakamoto, and M. Hashimoto
IDENTIFICATION OF ESTERASES EXPRESSED IN CACO-2 CELLS AND EFFECTS OF THEIR HYDROLYZING ACTIVITY IN PREDICTING HUMAN INTESTINAL ABSORPTION
Drug Metab. Dispos., August 1, 2005; 33(8): 1185 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. N. Tallman, J. K. Ritter, and P. C. Smith
DIFFERENTIAL RATES OF GLUCURONIDATION FOR 7-ETHYL-10-HYDROXY-CAMPTOTHECIN (SN-38) LACTONE AND CARBOXYLATE IN HUMAN AND RAT MICROSOMES AND RECOMBINANT UDP-GLUCURONOSYLTRANSFERASE ISOFORMS
Drug Metab. Dispos., July 1, 2005; 33(7): 977 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Harel, J. L. Hyatt, B. Brumshtein, C. L. Morton, K. J. P. Yoon, R. M. Wadkins, I. Silman, J. L. Sussman, and P. M. Potter
The Crystal Structure of the Complex of the Anticancer Prodrug 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica Acetylcholinesterase Provides a Molecular Explanation for Its Cholinergic Action
Mol. Pharmacol., June 1, 2005; 67(6): 1874 - 1881.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Yu, W. D. Shannon, M. A. Watson, and H. L. McLeod
Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 2053 - 2062.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Soepenberg, H. Dumez, J. Verweij, F. A. de Jong, M. J.A. de Jonge, J. Thomas, F. A.L.M. Eskens, R. H.N. van Schaik, J. Selleslach, J. ter Steeg, et al.
Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors
Clin. Cancer Res., February 15, 2005; 11(4): 1504 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. J. P. Yoon, J. L. Hyatt, C. L. Morton, R. E. Lee, P. M. Potter, and M. K. Danks
Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application
Mol. Cancer Ther., August 1, 2004; 3(8): 903 - 909.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. M. Wadkins, J. L Hyatt, K. J. P. Yoon, C. L. Morton, R. E. Lee, K. Damodaran, P. Beroza, M. K. Danks, and P. M. Potter
Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity
Mol. Pharmacol., June 1, 2004; 65(6): 1336 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. D. Prados, W.K.A. Yung, K. A. Jaeckle, H. I. Robins, M. P. Mehta, H. A. Fine, P. Y. Wen, T. F. Cloughesy, S. M. Chang, M. K. Nicholas, et al.
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
Neuro-oncol, January 1, 2004; 6(1): 44 - 54.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H. Stubdal, N. Perin, M. Lemmon, P. Holman, M. Bauzon, P. M. Potter, M. K. Danks, A. Fattaey, T. Dubensky, and L. Johnson
A Prodrug Strategy Using ONYX-015-Based Replicating Adenoviruses to Deliver Rabbit Carboxylesterase to Tumor Cells for Conversion of CPT-11 to SN-38
Cancer Res., October 15, 2003; 63(20): 6900 - 6908.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Wierdl, A. Wall, C. L. Morton, J. Sampath, M. K. Danks, J. D. Schuetz, and P. M. Potter
Carboxylesterase-Mediated Sensitization of Human Tumor Cells to CPT-11 Cannot Override ABCG2-Mediated Drug Resistance
Mol. Pharmacol., August 1, 2003; 64(2): 279 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Oosterhoff, M. A. Witlox, V. W. van Beusechem, H. J. Haisma, G. R. Schaap, J. Bras, F. A. Kruyt, B. Molenaar, E. Boven, P. I. J. M. Wuisman, et al.
Gene-directed Enzyme Prodrug Therapy for Osteosarcoma: Sensitization to CPT-11 in Vitro and in Vivo by Adenoviral Delivery of a Gene Encoding Secreted Carboxylesterase-2
Mol. Cancer Ther., August 1, 2003; 2(8): 765 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Xu and M. A. Villalona-Calero
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Ann. Onc., December 1, 2002; 13(12): 1841 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
F. Desmoulin, V. Gilard, M. Malet-Martino, and R. Martino
Metabolism of Capecitabine, an Oral Fluorouracil Prodrug: 19F NMR Studies in Animal Models and Human Urine
Drug Metab. Dispos., November 1, 2002; 30(11): 1221 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Xu, W. Zhang, M. K. Ma, and H. L. McLeod
Human Carboxylesterase 2 Is Commonly Expressed in Tumor Tissue and Is Correlated with Activation of Irinotecan
Clin. Cancer Res., August 1, 2002; 8(8): 2605 - 2611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H. Wu, B. Yan, R. Humerickhouse, and M. E. Dolan
Irinotecan Activation by Human Carboxylesterases in Colorectal Adenocarcinoma Cells
Clin. Cancer Res., August 1, 2002; 8(8): 2696 - 2700.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F.S. Kehrer, R. H.J. Mathijssen, J. Verweij, P. de Bruijn, and A. Sparreboom
Modulation of Irinotecan Metabolism by Ketoconazole
J. Clin. Oncol., July 15, 2002; 20(14): 3122 - 3129.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Sai, N. Kaniwa, S. Ozawa, and J.-i. Sawada
A New Metabolite of Irinotecan in Which Formation Is Mediated by Human Hepatic Cytochrome P-450 3a4
Drug Metab. Dispos., November 1, 2001; 29(11): 1505 - 1513.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. M. Wadkins, C. L. Morton, J. K. Weeks, L. Oliver, M. Wierdl, M. K. Danks, and P. M. Potter
Structural Constraints Affect the Metabolism of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by Carboxylesterases
Mol. Pharmacol., August 1, 2001; 60(2): 355 - 362.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.